Table 1.
Baseline HRs and cardioaccelerator responses to muscle contraction
| Static Contraction |
Intermittent Isometric Contraction |
||||
|---|---|---|---|---|---|
| Number of Rats/Group | Baseline HR | ΔHR | Baseline HR | ΔHR | |
| Freely perfused rats | |||||
| Control | 8 | 380 ± 19 | 8 ± 1 | 371 ± 15 | 7 ± 2 |
| IL-6/sIL-6r (intra-arterial) | 373 ± 17 | 8 ± 1 | 371 ± 16 | 11 ± 2 | |
| Control | 5 | 383 ± 17 | 11 ± 4 | 380 ± 20 | 9 ± 5 |
| sgp130 + IL-6/sIL-6r (intra-arterial) | 344 ± 14* | 7 ± 2 | 337 ± 18* | 10 ± 4 | |
| Control | 6 | 358 ± 10 | 9 ± 1 | 342 ± 17 | 6 ± 1 |
| IL-6 (intra-arterial) | 323 ± 18 | 6 ± 1 | 322 ± 19 | 7 ± 2 | |
| Control | 6 | 352 ± 19 | 8 ± 2 | 346 ± 19 | 8 ± 4 |
| IL-6/sIL-6r (intravenous) | 339 ± 18 | 6 ± 3 | 351 ± 23 | 6 ± 2 | |
| Control | 6 | 316 ± 16 | 9 ± 2 | 309 ± 11 | 10 ± 2 |
| 50 ng sgp130 (intra-arterial) | 310 ± 17 | 7 ± 1 | 309 ± 17 | 9 ± 2 | |
| Control | 6 | 340 ± 28 | 10 ± 2 | 335 ± 25 | 9 ± 3 |
| 500 ng sgp130 (intra-arterial) | 325 ± 26 | 10 ± 5 | 334 ± 26 | 10 ± 1 | |
| Ligated rats | |||||
| Control | 7 | 363 ± 16 | 4 ± 1 | 369 ± 14 | 5 ± 1 |
| 50 ng sgp130 (intra-arterial) | 344 ± 22* | 6 ± 1 | 348 ± 20* | 4 ± 1 | |
| Control | 4 | 344 ± 12 | 7 ± 2 | 342 ± 16 | 7 ± 1 |
| 50 ng sgp130 (intravenous) | 334 ± 7 | 8 ± 2 | 339 ± 6 | 4 ± 1* | |
Values are means ± SE (in beats/min).
HR, heart rate; ΔHR, cardioaccelerator response to hindlimb muscle contraction; sIL-6r, soluble IL-6 receptor; sgp130, soluble glycoprotein 130.
*
P < 0.05 vs. the corresponding control value.